Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CPB1 | P15086 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15012280 | 0.89 | L3MBTL1 (0.46) | ALDH1A1GAATSHRCPB1EPHX1 | |
| SCHEMBL16145800 | 0.86 | ALDH1A1 (0.38) | ALDH1A1GAATSHRCPB1KMT2A | |
| SCHEMBL5308210 | 0.80 | L3MBTL1 (0.54) | ALDH1A1KMT2A | |
| SCHEMBL1836110 | 0.80 | L3MBTL1 (0.54) | ALDH1A1KMT2A | |
| SCHEMBL8822994 | 0.80 | L3MBTL1 (0.50) | KMT2A | |
| SCHEMBL11269209 | 0.79 | L3MBTL1 (0.44) | KMT2ACTSLCA1 | |
| SCHEMBL9625028 | 0.79 | ALDH1A1 (0.37) | ALDH1A1KMT2ACA1CA2 | |
| SCHEMBL8579544 | 0.78 | TLR4 (0.35) | KMT2A | |
| SCHEMBL14709165 | 0.77 | ALDH1A1 (0.44) | ALDH1A1GAATSHRCPB1CTSL | |
| SCHEMBL8581377 | 0.77 | KMT2A (0.33) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303363-A1 | Preparation and Use of Isolactosamine and Intermediates therefor | GLYCOM A/S (DK) | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303363-A1 | Preparation and Use of Isolactosamine and Intermediates therefor | GALE, B4GALT1, GNE | ALDH1A1 889/4885GAA 382/4885TSHR 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.